First Trust Advisors LP Sells 13,643 Shares of Revvity Inc. $RVTY

First Trust Advisors LP lowered its stake in shares of Revvity Inc. (NYSE:RVTY) by 10.7% during the first quarter, Holdings Channel.com reports. The institutional investor owned 114,096 shares of the company’s stock after selling 13,643 shares during the quarter. First Trust Advisors LP’s holdings in Revvity were worth $9,996,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. AQR Capital Management LLC raised its position in shares of Revvity by 5.2% in the 1st quarter. AQR Capital Management LLC now owns 8,449 shares of the company’s stock valued at $883,000 after acquiring an additional 420 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Revvity by 6.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 11,776 shares of the company’s stock valued at $1,246,000 after purchasing an additional 744 shares during the period. Millennium Management LLC increased its stake in Revvity by 102.0% in the first quarter. Millennium Management LLC now owns 69,401 shares of the company’s stock valued at $7,343,000 after purchasing an additional 35,048 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in Revvity by 45.5% in the first quarter. Goldman Sachs Group Inc. now owns 607,104 shares of the company’s stock valued at $64,232,000 after purchasing an additional 189,871 shares in the last quarter. Finally, Focus Partners Wealth raised its holdings in Revvity by 13.0% in the first quarter. Focus Partners Wealth now owns 7,028 shares of the company’s stock worth $744,000 after purchasing an additional 811 shares during the period. 86.65% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the stock. Wolfe Research started coverage on shares of Revvity in a research report on Tuesday, June 2nd. They set a “peer perform” rating on the stock. Evercore restated an “outperform” rating and issued a $125.00 price objective on shares of Revvity in a research report on Monday, July 6th. TD Cowen reaffirmed a “buy” rating on shares of Revvity in a research note on Wednesday, July 15th. Robert W. Baird set a $117.00 target price on Revvity in a report on Wednesday, May 6th. Finally, Sanford C. Bernstein initiated coverage on Revvity in a research note on Friday, June 26th. They issued a “market perform” rating and a $115.00 target price for the company. Three research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $108.36.

Revvity Stock Performance

Shares of RVTY opened at $112.79 on Friday. The firm has a market cap of $12.58 billion, a P/E ratio of 53.96, a PEG ratio of 2.23 and a beta of 1.09. Revvity Inc. has a twelve month low of $81.22 and a twelve month high of $118.30. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.41 and a current ratio of 1.72. The firm’s 50 day moving average price is $106.51 and its two-hundred day moving average price is $99.91.

Revvity (NYSE:RVTY) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $1.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.04. Revvity had a net margin of 8.26% and a return on equity of 8.00%. The company had revenue of $711.12 million during the quarter, compared to the consensus estimate of $704.07 million. During the same quarter in the prior year, the firm earned $1.01 earnings per share. The firm’s revenue was up 7.0% compared to the same quarter last year. Revvity has set its FY 2026 guidance at 5.200-5.300 EPS. On average, analysts forecast that Revvity Inc. will post 5.25 EPS for the current fiscal year.

Revvity Company Profile

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.